GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Ending Cash Position

Immunovia AB (LTS:0G8X) Ending Cash Position : kr25.32 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Immunovia AB Ending Cash Position?

Immunovia AB's Ending Cash Position for the quarter that ended in Dec. 2024 was kr25.32 Mil.

Immunovia AB's quarterly Ending Cash Position increased from Jun. 2024 (kr36.76 Mil) to Sep. 2024 (kr54.20 Mil) but then declined from Sep. 2024 (kr54.20 Mil) to Dec. 2024 (kr25.32 Mil).

Immunovia AB's annual Ending Cash Position declined from Dec. 2022 (kr106.04 Mil) to Dec. 2023 (kr76.79 Mil) and declined from Dec. 2023 (kr76.79 Mil) to Dec. 2024 (kr25.32 Mil).

Immunovia AB Ending Cash Position Historical Data

The historical data trend for Immunovia AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Ending Cash Position Chart

Immunovia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 468.46 287.41 106.04 76.79 25.32

Immunovia AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.79 51.18 36.76 54.20 25.32

Immunovia AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Immunovia AB's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=76.788+-51.47
=25.32

Immunovia AB's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=54.204+-28.886
=25.32

Immunovia AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Ending Cash Position
Comparable Companies
NGM:LUMITO XSAT:GEAN OSTO:AROC NGM:LEVBIO NGM:ATANA OSTO:SENZA OSTO:PROGEN XSAT:SPERM TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX LH
Traded in Other Exchanges
IMMNOV:Sweden 1YR:Germany
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Website
https://www.immunovia.com
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Immunovia AB Headlines

No Headlines